Home > Insider Trading > Filing (0000899243-21-040245)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1745020	Theseus Pharmaceuticals Inc.	THRX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1361712	Otello Stampacchia	888 Boylston Street, Suite 1111 Boston MA 02199	No	No	No	Yes
1652863	Anne-Mari Paster	888 Boylston Street, Suite 1111 Boston MA 02199	No	No	No	Yes
1722050	Claudio Nessi	888 Boylston Street, Suite 1111 Boston MA 02199	No	No	No	Yes
1757917	Omega Fund Vi, L.p.	888 Boylston Street, Suite 1111 Boston MA 02199	No	No	No	Yes
1826584	Omega Fund Vi Gp Manager, Ltd.	888 Boylston Street, Suite 1111 Boston MA 02199	No	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-10-12	523,979	$0.00	523,979	No	4	C	Direct
Common Stock	Acquisiton	2021-10-12	187,500	$16.00	711,479	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2021-10-12	693,152	$0.00	523,979	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

Omega Fund VI, L.P. ("Omega VI") held 693,152 shares of the Issuer's Series B Preferred Stock. On October 12, 2021, the Series B Preferred Stock automatically converted into 523,979 shares of the Issuer's Common Stock on a 1-for-1.32286 reverse split basis, immediately prior to and in connection with the closing of a public offering of the Issuer's securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") and without payment of further consideration.
The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI.
As of October 12, 2021 and after giving effect to the transactions reported above, Omega VI holds less than 10% of the outstanding shares of the Issuer's Common Stock.